MARKET

TLPH

TLPH

Talphera Inc
NASDAQ
0.5300
+0.0350
+7.07%
Closed 16:00 04/01 EDT
OPEN
0.6000
PREV CLOSE
0.4950
HIGH
0.6000
LOW
0.5006
VOLUME
37.25K
TURNOVER
--
52 WEEK HIGH
1.270
52 WEEK LOW
0.4500
MARKET CAP
9.03M
P/E (TTM)
-0.7803
1D
5D
1M
3M
1Y
5Y
1D
Strategic Advancements and FDA Agreement Propel Talphera’s Positive Outlook with Buy Rating
TipRanks · 9h ago
Talphera Reports 2024 Financial Results and Study Update
TipRanks · 16h ago
Talphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of Niyad
Seeking Alpha · 21h ago
Talphera Expects Registrational NEPHRO CRRT Study To Be Completed By The End Of 2025
Benzinga · 22h ago
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 23h ago
TALPHERA: EXPECTED TO PROVIDE CAPITAL THROUGH TARGET COMPLETION OF NEPHRO STUDY IN Q4 OF 2025
Reuters · 1d ago
*Talphera 4Q Loss/Shr 7c >TLPH
Dow Jones · 1d ago
*Talphera: Cash and Cash Equivalents Balance $8.9M as of Dec 31 >TLPH
Dow Jones · 1d ago
More
About TLPH
More
Talphera, Inc., formerly AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is nafamostat formulation for direct intravenous (IV) infusion that shall be investigated and developed as a potential anti-viral for the treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. The Company is also engaged in developing two pre-filled syringes, namely Fedsyra and PFS-02.
Recently
Symbol
Price
%Change

Webull offers Talphera Inc stock information, including NASDAQ: TLPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TLPH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TLPH stock methods without spending real money on the virtual paper trading platform.